

NATIONAL FUNDING/ACCESS DECISIONS

NICE decisions

- ▶ Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) NICE TA223 Naftidrofuryl oxalate is an option for the treatment of intermittent claudication in patients with peripheral arterial disease in whom vasodilator therapy is considered appropriate.

www.nice.org.uk/guidance/ta223

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Capsule

CAUTIONARY AND ADVISORY LABELS 25, 27

▶ Naftidrofuryl oxalate (Non-proprietary)

Naftidrofuryl oxalate 100 mg Naftidrofuryl 100mg capsules | 84 capsule **[PoM]** £7.50 DT = £5.26

▶ Praxilene (Merck Serono Ltd)

Naftidrofuryl oxalate 100 mg Praxilene 100mg capsules | 84 capsule **[PoM]** £8.10 DT = £5.26

Pentoxifylline

06-Feb-2020

(Xopentiflyline)

● INDICATIONS AND DOSE

Peripheral vascular disease | Venous leg ulcer (adjunct)

▶ BY MOUTH

▶ Adult: 400 mg 2–3 times a day

- **UNLICENSED USE** Use of pentoxifylline as adjunct therapy for venous leg ulcers is an unlicensed indication.

- **CONTRA-INDICATIONS** Acute myocardial infarction · cerebral haemorrhage · extensive retinal haemorrhage · severe cardiac arrhythmias

- **CAUTIONS** Avoid in Acute porphyrias p. 1120 · coronary artery disease · hypotension

- **INTERACTIONS** → Appendix 1: pentoxifylline

- **SIDE-EFFECTS** Agitation · angina pectoris · angioedema · arrhythmias · bronchospasm · cholestasis · constipation · diarrhoea · dizziness · gastrointestinal discomfort · gastrointestinal disorder · haemorrhage · headache · hot flush · hypersalivation · hypotension · leucopenia · meningitis aseptic · nausea · neutropenia · skin reactions · sleep disorder · thrombocytopenia · vomiting

- **PREGNANCY** Manufacturer advises avoid—no information available.

- **BREAST FEEDING** Present in milk—manufacturer advises use only if potential benefit outweighs risk.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment.

Dose adjustments Manufacturer advises consider dose reduction in severe impairment.

- **RENAL IMPAIRMENT**

Dose adjustments Reduce dose by 30–50% if eGFR less than 30 mL/minute/1.73 m².

- **NATIONAL FUNDING/ACCESS DECISIONS**

NICE decisions

- ▶ Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) NICE TA223 Pentoxifylline is not recommended for the treatment of intermittent claudication in patients with peripheral arterial disease; patients currently receiving this treatment should have the option to continue until they and their clinician consider it appropriate to stop.

www.nice.org.uk/guidance/ta223

- **LESS SUITABLE FOR PRESCRIBING** Less suitable for prescribing.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 21, 25

▶ Trental (Sanofi)

Pentoxifylline 400 mg Trental 400 modified-release tablets | 90 tablet **[PoM]** £19.39 DT = £19.39

10.1 Vein malformations

SCLEROSANTS

Sodium tetradecyl sulfate

29-Apr-2020

● INDICATIONS AND DOSE

Sclerotherapy of reticular veins and spider veins in legs and varicose veins

▶ BY INTRAVENOUS INJECTION

▶ Adult: Test dose recommended before each treatment (consult product literature)

- **CONTRA-INDICATIONS** Acute infection · asthma · blood disorders · deep vein thrombosis · high risk of thromboembolism · hyperthyroidism · inability to walk · neoplasm · occlusive arterial disease · phlebitis · pulmonary embolism · recent acute superficial thrombophlebitis · recent surgery · respiratory disease · significant valvular incompetence in deep veins · skin disease · symptomatic patent foramen ovale (if administered as foam) · uncontrolled diabetes mellitus · varicose veins caused by tumours (unless tumour removed)

- **CAUTIONS** Arterial disease · asymptomatic patent foramen ovale (use smaller volumes and avoid Valsalva manoeuvre immediately after administration) · extravasation may cause necrosis of tissues · history of migraine (use smaller volumes) · resuscitation facilities must be available · venous insufficiency with lymphoedema (pain and inflammation may worsen)

● SIDE-EFFECTS

- ▶ **Common or very common** Embolism and thrombosis · pain · paraesthesia

- ▶ **Uncommon** Skin reactions · telangiectasia

- ▶ **Rare or very rare** Arterial spasm · asthenia · asthma · cerebrovascular insufficiency · chest pressure · circulatory collapse · confusion · cough · diarrhoea · dry mouth · dyspnoea · fever · headaches · hot flush · hypersensitivity · local exfoliation · nausea · nerve damage · palpitations · presyncope · soft tissue necrosis · tongue swelling · vasculitis · vision disorders · vomiting

- **PREGNANCY** Avoid unless benefits outweigh risks—no information available.

- **BREAST FEEDING** Use with caution—no information available.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXCIPIENTS: May contain Benzyl alcohol

▶ Fibro-Vein (STD Pharmaceutical Products Ltd)

Sodium tetradecyl sulfate 2 mg per 1 ml Fibrovein 0.2% solution for injection 5ml vials | 10 vial **[PoM]** £73.61

Sodium tetradecyl sulfate 5 mg per 1 ml Fibrovein 0.5% solution for injection 2ml ampoules | 5 ampoule **[PoM]** £18.93

Sodium tetradecyl sulfate 10 mg per 1 ml Fibrovein 1% solution for injection 2ml ampoules | 5 ampoule **[PoM]** £22.61

Sodium tetradecyl sulfate 30 mg per 1 ml Fibrovein 3% solution for injection 2ml ampoules | 5 ampoule **[PoM]** £33.65

Fibrovein 3% solution for injection 5ml vials | 10 vial **[PoM]** £166.66